354 related articles for article (PubMed ID: 36273186)
1. High-dose Intensity-modulated proton therapy versus Standard-dose Intensity-modulated RadIation therapy for esophageal squamous cell carcinoma (HI-SIRI): study protocol for a randomized controlled clinical trial.
Lertbutsayanukul C; Kitpanit S; Kannarunimit D; Chakkabat C; Oonsiri S; Thephamongkhol K; Puataweepong P; Katanyoo K; Sukhaboon J; Tovanabut C; Chongsathientham S; Treeratsapanich P; Soonthornrak J; Prayongrat A
Trials; 2022 Oct; 23(1):897. PubMed ID: 36273186
[TBL] [Abstract][Full Text] [Related]
2. A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol.
Gao LR; Wang X; Han W; Deng W; Li C; Wang X; Zhao Y; Ni W; Chang X; Zhou Z; Deng L; Wang W; Liu W; Liang J; Zhang T; Bi N; Wang J; Zhai Y; Feng Q; Lv J; Li L; Xiao Z
BMC Cancer; 2020 Sep; 20(1):901. PubMed ID: 32962674
[TBL] [Abstract][Full Text] [Related]
3. DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer.
Petkar I; Rooney K; Roe JW; Patterson JM; Bernstein D; Tyler JM; Emson MA; Morden JP; Mertens K; Miles E; Beasley M; Roques T; Bhide SA; Newbold KL; Harrington KJ; Hall E; Nutting CM
BMC Cancer; 2016 Oct; 16(1):770. PubMed ID: 27716125
[TBL] [Abstract][Full Text] [Related]
4. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
[TBL] [Abstract][Full Text] [Related]
5. Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study.
Welsh J; Gomez D; Palmer MB; Riley BA; Mayankkumar AV; Komaki R; Dong L; Zhu XR; Likhacheva A; Liao Z; Hofstetter WL; Ajani JA; Cox JD
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1336-42. PubMed ID: 21470796
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study.
Jeter MD; Gomez D; Nguyen QN; Komaki R; Zhang X; Zhu X; O'Reilly M; Fossella FV; Xu T; Wei X; Wang H; Yang W; Tsao A; Mohan R; Liao Z
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):730-737. PubMed ID: 29248169
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiotherapy for Patients With Inoperable Esophageal Squamous Cell Carcinoma Undergoing Curative-Intent Concurrent Chemoradiotherapy.
Chang CL; Lin KC; Chen WM; Shia BC; Wu SY
J Thorac Oncol; 2024 May; 19(5):818-828. PubMed ID: 38154513
[TBL] [Abstract][Full Text] [Related]
8. Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and standard-dose intensity-modulated radiotherapy in locally advanced esophageal squamous cell carcinoma: a retrospective study.
Lan W; Lihong L; Chun H; Shutang L; Qi W; Liang X; Xiaoning L; Likun L
Strahlenther Onkol; 2022 Sep; 198(9):802-811. PubMed ID: 35029718
[TBL] [Abstract][Full Text] [Related]
9. A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol.
Li C; Wang X; Wang X; Han C; Wang P; Pang Q; Chen J; Sun X; Wang L; Zhang W; Lin Y; Ge X; Zhou Z; Ni W; Chang X; Liang J; Deng L; Wang W; Zhao Y; Xiao Z
BMC Cancer; 2019 Apr; 19(1):397. PubMed ID: 31036088
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous modulated accelerated radiation therapy for esophageal cancer: a feasibility study.
Zhang WZ; Chen JZ; Li DR; Chen ZJ; Guo H; Zhuang TT; Li DS; Zhou MZ; Chen CZ
World J Gastroenterol; 2014 Oct; 20(38):13973-80. PubMed ID: 25320535
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) combined with nimotuzumab for locally advanced esophageal squamous cell carcinoma (ESCC): A phase II clinical trial.
Wang L; Liu L; Cao Y; Chen X; Liu S; Li X; Han J; Wang Q; Han C
BMC Cancer; 2024 Jun; 24(1):679. PubMed ID: 38831450
[TBL] [Abstract][Full Text] [Related]
12. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.
Li X; Kitpanit S; Lee A; Mah D; Sine K; Sherman EJ; Dunn LA; Michel LS; Fetten J; Zakeri K; Yu Y; Chen L; Kang JJ; Gelblum DY; McBride SM; Tsai CJ; Riaz N; Lee NY
JAMA Netw Open; 2021 Jun; 4(6):e2113205. PubMed ID: 34143193
[TBL] [Abstract][Full Text] [Related]
13. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Oropharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.
Youssef I; Yoon J; Mohamed N; Zakeri K; Press RH; Chen L; Gelblum DY; McBride SM; Tsai CJ; Riaz N; Yu Y; Cohen MA; Dunn LA; Ho AL; Wong RJ; Michel LS; Boyle JO; Singh B; Kriplani A; Ganly I; Sherman EJ; Pfister DG; Fetten J; Lee NY
JAMA Netw Open; 2022 Nov; 5(11):e2241538. PubMed ID: 36367724
[TBL] [Abstract][Full Text] [Related]
14. Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis.
Blanchard P; Garden AS; Gunn GB; Rosenthal DI; Morrison WH; Hernandez M; Crutison J; Lee JJ; Ye R; Fuller CD; Mohamed AS; Hutcheson KA; Holliday EB; Thaker NG; Sturgis EM; Kies MS; Zhu XR; Mohan R; Frank SJ
Radiother Oncol; 2016 Jul; 120(1):48-55. PubMed ID: 27342249
[TBL] [Abstract][Full Text] [Related]
15. The feasibility of dose escalation using intensity-modulated radiotherapy (IMRT) and intensity-modulated proton therapy (IMPT) with FDG PET/CT guided in esophageal cancer.
Zhang Y; Fan B; Sun T; Xu J; Yin Y; Chen Z; Zhu J; Yu J; Hu M
J Cancer Res Ther; 2022 Sep; 18(5):1261-1267. PubMed ID: 36204871
[TBL] [Abstract][Full Text] [Related]
16. Glioblastoma radiotherapy using Intensity modulated Radiotherapy (IMRT) or proton Radiotherapy-GRIPS Trial (Glioblastoma Radiotherapy via IMRT or Proton BeamS): a study protocol for a multicenter, prospective, open-label, randomized, two-arm, phase III study.
König L; Jäkel C; von Knebel Doeberitz N; Kieser M; Eberle F; Münter M; Debus J; Herfarth K
Radiat Oncol; 2021 Dec; 16(1):240. PubMed ID: 34930368
[TBL] [Abstract][Full Text] [Related]
17. Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: A case-matched control analysis.
Holliday EB; Kocak-Uzel E; Feng L; Thaker NG; Blanchard P; Rosenthal DI; Gunn GB; Garden AS; Frank SJ
Med Dosim; 2016; 41(3):189-94. PubMed ID: 27158021
[TBL] [Abstract][Full Text] [Related]
18. Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or Intensity-modulated radiation therapy.
Shiraishi Y; Xu C; Yang J; Komaki R; Lin SH
Radiother Oncol; 2017 Oct; 125(1):48-54. PubMed ID: 28917586
[TBL] [Abstract][Full Text] [Related]
19. Acute Toxicities and Short-Term Patient Outcomes After Intensity-Modulated Proton Beam Radiation Therapy or Intensity-Modulated Photon Radiation Therapy for Esophageal Carcinoma: A Mayo Clinic Experience.
Bhangoo RS; DeWees TA; Yu NY; Ding JX; Liu C; Golafshar MA; Rule WG; Vora SA; Ross HJ; Ahn DH; Beamer SE; Jaroszewski DE; Hallemeier CL; Liu W; Ashman JB; Sio TT
Adv Radiat Oncol; 2020; 5(5):871-879. PubMed ID: 33083649
[TBL] [Abstract][Full Text] [Related]
20. Intensity-modulated versus 3-dimensional conformal radiotherapy in the definitive treatment of esophageal cancer: comparison of outcomes and acute toxicity.
Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
Radiat Oncol; 2017 Aug; 12(1):131. PubMed ID: 28810885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
